Thomas K. Equels, M.S. J.D.
THOMAS K. EQUELS, M.S., J.D., was named Chief Executive Officer in February 2016, served as President since August 2015, has been a Director since 2008 and presently serves as our Executive Vice Chairman, Secretary and General Counsel and Litigation Counsel. Mr. Equels previously served as Chief Financial Officer from December 2013 to February 2016. While serving full-time at Hemispherx, Mr. Equels has been the President and Managing Director of the Equels Law Firm based in Miami Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. On numerous occasions, Mr. Equels has been the court appointed receiver to turnaround distressed companies. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree in Management from Troy. He is a member of the Florida Bar Association and the American Bar Association
ADAM PASCALE was named Chief Financial Officer in February 2016, in addition to his current responsibilities as Chief Accounting Officer. Mr. Pascale has been employed with Hemispherx since 1996, with more than two decades of public accounting experience and prior public company experience. He earned a Bachelor of Arts (BA) degree in Accounting and Finance from Rutgers University. Mr. Pascale served for several years as a CPA prior to joining Hemispherx, and is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants.
DAVID R. STRAYER, M.D. was appointed Chief Scientific Officer in Feburary 2016 and has acted served as our Medical Director since 1986. Dr. Strayer, based upon this experience, is the foremost medical expert on Ampligen and Alferon in the World. He has served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.
Peter W. Rodino III, Esq.
PETER W. RODINO, III, Esq., was named Executive Director for Governmental Relations and General Counsel in October 2016. Mr. Rodino was appointed a Director of the Company in July 2013 and served in that capacity until his resignation to permit him to serve the Company in this new capacity. While on the Board, he served as Lead Director, Chairman and Financial Expert of the Audit Committee, a member of the Compensation Committee and a member of the Governance and Nomination Committee.appointed Lead Director in September 2015 and has served as a member of to the Board of Directors since July 2013. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. For the past 17 years, as founder and president of Rodino Consulting, Mr. Rodino has provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.
WAYNE S. SPRINGATE has served as Senior Vice President of Operations since May 2011 after joining Hemispherx in 2002 as Vice President of Business Development. Mr. Springate came on board when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facility. He led the consolidation of our Rockville facility to our New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to our production facility in New Brunswick. Currently he is managing a capital improvement budget to enhance our Alferon® facility in accordance with current Good Manufacturing Practice (“cGMP”). Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.